AMGN
Amgen Inc.Healthcare · $203.7B market cap
Verdict
Share price
$403.04
close of Oct 3, 2026
Fair value
$336.52
Sticker Price
Payback Price
$134.61
buy price
AMGN is Overpriced: at $403.04 it trades 20% above its fair value of $336.52. Its buy price (Payback Price) is $134.61, 67% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.
How we valued it
Dividend Discount Model. It has paid a dividend for 10+ years in a row, raised it most years, and yields over 2%. For a steady payer like this, the dividend is the best guide to value.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow AMGN
Get notified when it reaches its buy price of $134.61. Free.
Create a free accountSuperinvestors
5 of the investors we track hold AMGN. In Q2 2026, 1 added. Who we track
David Katz
Matrix Asset Advisors · as of Q2 2026
$37.2M
102,817 shares
Torray Funds
Torray Funds · as of Q2 2026
$21.6M
59,771 shares
Dodge & Cox Funds
Dodge & Cox Funds · as of Q2 2026
$4.6M
12,817 shares
Mairs & Power Funds
Mairs & Power Funds · as of Q2 2026
$1.8M
4,924 shares
Steven Check
Check Capital Management · as of Q2 2026
$1.4M
3,885 shares
Moves in Q2 2026
Added: Torray Funds
Insider activity
Since Aug 6, 2026: no open-market purchases, 4 sales worth $2.5M and 9 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Khosla Rachna
SVP, Business Development · 2026-08-13
Sold
$521K
Khosla Rachna
SVP, Business Development · 2026-08-11
Sold
$825K
Grygiel Nancy A.
SVP & CCO · 2026-08-06
Sold
$402K
Miller Derek
SVP, Human Resources · 2026-08-06
Sold
$733K
Other filings
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience…
Drug Manufacturers - General
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works